Ophysio Inc.
Biotech · Defunct
Genetically engineered human embryonic stem cells with integrated suicide gene constructs for selective ablation of tumorigenic and off-target differentiated cells in regenerative therapies
- Grants
- $3.8M
- 7 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201420152016201720182019
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · In vitro maturation of BMP-7-responsive pancreatic beta cell progenitors by oxygen modulation technology | $224,985 | |
| Federal grant | Department of Health and Human Services · Phase I · In vitro maturation of BMP-7-responsive pancreatic beta cell progenitors by oxygen modulation technology | $224,985 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase II · technologyIn vitro maturation of BMP responsive pancraeatic beta cell progenitors by oxygen modulation | $1,443,038 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase II · technologyIn vitro maturation of BMP-7-responsive pancraeatic beta cell progenitors by oxygen modulation | $732,148 | |
| Federal grant | Department of Health and Human Services · Phase I · Preclinical characterization of THR-123 to induce pancreatic beta cell regeneration (Phase I) | $223,876 | |
| Federal grant | Department of Health and Human Services · Phase II · technologyIn vitro maturation of BMP-7-responsive pancraeatic beta cell progenitors by oxygen modulation | $710,890 | |
| Federal grant | Department of Health and Human Services · Phase I · Targeting a double fail-safe construct to prevent tumorigenesis and select pancreatic endocrine cells from human embryonic stem cells | $224,339 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 3268 | PROBIOME THERAPEUTICS, INC. | — | — |
| 3269 | Outer Biosciences Inc | — | $23M |
| 3270 | Prelenia | — | — |
| 3271 | Ophysio Inc. | — | — |
| 3272 | ONCOC4, INC. | — | $50M |
| 3273 | CLUE GENETICS INC. | — | — |
| 3274 | Ibex Investment Holdings LLC | — | $5.0M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.